CSF hypocretin levels in Guillain-Barré syndrome and other inflammatory neuropathies.
CSF hypocretin-1 was measured in 28 Guillain-Barré syndrome (GBS), 12 Miller-Fisher syndrome, 12 chronic inflammatory demyelinating polyneuropathy (CIDP), and 48 control subjects. Seven GBS subjects had undetectably low hypocretin-1 levels (<100 pg/mL). Hypocretin-1 levels were moderately reduced in an additional 11 GBS, 5 Miller-Fisher syndrome, and 1 CIDP subject. Low levels in GBS occurred early in the disease and were associated with upper CNS level abnormalities.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002352:Carrier Proteins / Q000134:cerebrospinal fluid*; D005260:Female; D020275:Guillain-Barre Syndrome / Q000134:cerebrospinal fluid* / Q000150:complications; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D008297:Male; D008875:Middle Aged; D019846:Miller Fisher Syndrome / Q000134:cerebrospinal fluid*; D009479:Neuropeptides / Q000134:cerebrospinal fluid* / Q000172:deficiency; D000068797:Orexins; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000134:cerebrospinal fluid*; D011782:Quadriplegia / Q000134:cerebrospinal fluid / Q000209:etiology; D016037:Single-Blind Method; D012893:Sleep Wake Disorders / Q000134:cerebrospinal fluid / Q000209:etiology
D002352:Carrier Proteins; C000596229:HCRT protein, human; D047908:Intracellular Signaling Peptides and Proteins; D009479:Neuropeptides; D000068797:Orexins